Wallerian degeneration: the innate-immune response to traumatic nerve injury

Journal of Neuroinflammation

Shlomo Rotshenker¹ 

[1] Dept. of Medical Neurobiology, IMRIC, Hebrew University, Faculty of Medicine, Jerusalem, Israel

关键词: myelin;    cytokine;    phagocytosis;    macrophage;    Wallerian degeneration;   

Others  :  1213144
DOI  :  10.1186/1742-2094-8-109

 received in 2011-06-22, accepted in 2011-08-30,  发布年份 2011

【 摘 要 】

Traumatic injury to peripheral nerves results in the loss of neural functions. Recovery by regeneration depends on the cellular and molecular events of Wallerian degeneration that injury induces distal to the lesion site, the domain through which severed axons regenerate back to their target tissues. Innate-immunity is central to Wallerian degeneration since innate-immune cells, functions and molecules that are produced by immune and non-immune cells are involved. The innate-immune response helps to turn the peripheral nerve tissue into an environment that supports regeneration by removing inhibitory myelin and by upregulating neurotrophic properties. The characteristics of an efficient innate-immune response are rapid onset and conclusion, and the orchestrated interplay between Schwann cells, fibroblasts, macrophages, endothelial cells, and molecules they produce. Wallerian degeneration serves as a prelude for successful repair when these requirements are met. In contrast, functional recovery is poor when injury fails to produce the efficient innate-immune response of Wallerian degeneration.

【 授权许可】

   
2011 Rotshenker; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Waller A: Experiments on the section of the glossopharyngeal and hypoglossal nerves of the frog, observations of the alterations produced thereby in the structure of their primitive fibers. Phil Transact Royal Soc London 1850, 140:423-429.
• [2]Stoll G, Jander S, Myers RR: Degeneration and regeneration of the peripheral nervous system: from Augustus Waller's observations to neuroinflammation. J Peripher Nerv Syst 2002, 7:13-27.
• [3]Vargas ME, Barres BA: Why is Wallerian degeneration in the CNS so slow? Annu Rev Neurosci 2007, 30:153-179.
• [4]Camara-Lemarroy CR, Guzman-de la Garza F, Fernandez-Garza NE: Molecular Inflammatory Mediators in Peripheral Nerve Degeneration and Regeneration. Neuroimmunomodulation 2010, 17:314-324.
• [5]Coleman MP, Freeman MR: Wallerian degeneration, wld(s), and nmnat. Annu Rev Neurosci 2010, 33:245-267.
• [6]Martini R, Fischer S, Lopez-Vales R, David S: Interactions between Schwann cells and macrophages in injury and inherited demyelinating disease. Glia 2008, 56:1566-1577.
• [7]Hoke A: Mechanisms of Disease: what factors limit the success of peripheral nerve regeneration in humans? Nat Clin Pract Neurol 2006, 2:448-454.
• [8]Hoke A, Brushart T: Introduction to special issue: Challenges and opportunities for regeneration in the peripheral nervous system. Exp Neurol 2009.
• [9]Krarup C, Archibald SJ, Madison RD: Factors that influence peripheral nerve regeneration: An electrophysiological study of the monkey median nerve. Ann Neurol 2002, 51:69-81.
• [10]Wood MD, Kemp SW, Weber C, Borschel GH, Gordon T: Outcome measures of peripheral nerve regeneration. Ann Anat 2011, 193:321-333.
• [11]Lubinska L: Early course of Wallerian degeneration in myelinated fibres of the rat phrenic nerve. Brain Res 1977, 130:47-63.
• [12]Beirowski B, Adalbert R, Wagner D, Grumme D, Addicks K, Ribchester R, et al.: The progressive nature of Wallerian degeneration in wild-type and slow Wallerian degeneration (WldS) nerves. BMC Neuroscience 2005, 6:6. BioMed Central Full Text
• [13]Gilliatt RW, Hjorth RJ: Nerve conduction during Wallerian degeneration in the baloon. J Neurol Neurosurg Psychiatry 1972, 35:335-341.
• [14]Cullen MJ: Freeze-fracture analysis of myelin membrane changes in Wallerian degeneration. J Neurocytol 1988, 17:105-115.
• [15]Tetzlaff W: Tight junction contact events and temporary gap junctions in the sciatic nerve fibres of the chicken during Wallerian degeneration and subsequent regeneration. J Neurocytol 1982, 11:839-858.
• [16]Reichert F, Saada A, Rotshenker S: Peripheral nerve injury induces Schwann cells to express two macrophage phenotypes: phagocytosis and the galactose-specific lectin MAC-2. J Neurosci 1994, 14:3231-3245.
• [17]Lunn ER, Perry VH, Brown MC, Rosen H, Gordon S: Absence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve. Eur J Neurosci 1989, 1:27-33.
• [18]Yan T, Feng Y, Zhai Q: Axon degeneration: Mechanisms and implications of a distinct program from cell death. Neurochemistry International 2010, 56:529-534.
• [19]Gilley J, Coleman MP: Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol 2010, 8:e1000300.
• [20]Conforti L, Tarlton A, Mack TGA, Mi W, Buckmaster EA, Wagner D, et al.: A Ufd2/D4Cole1e chimeric protein and overexpression of Rbp7 in the slow Wallerian degeneration (WldS) mouse. Proceedings of the National Academy of Sciences 2000, 97:11377-11382.
• [21]Sasaki Y, Vohra BPS, Baloh RH, Milbrandt J: Transgenic Mice Expressing the Nmnat1 Protein Manifest Robust Delay in Axonal Degeneration In Vivo. The Journal of Neuroscience 2009, 29:6526-6534.
• [22]Conforti L, Fang G, Beirowski B, Wang MS, Sorci L, Asress S, et al.: NAD+ and axon degeneration revisited: Nmnat1 cannot substitute for WldS to delay Wallerian degeneration. Cell Death Differ 2006, 14:116-127.
• [23]Avery MA, Sheehan AE, Kerr KS, Wang J, Freeman MR: WldS requires Nmnat1 enzymatic activity and N16-VCP interactions to suppress Wallerian degeneration. J Cell Biol 2009, 184:501-513.
• [24]Guertin AD, Zhang DP, Mak KS, Alberta JA, Kim HA: Microanatomy of axon/glial signaling during Wallerian degeneration. J Neurosci 2005, 25:3478-3487.
• [25]Kwon YK, Bhattacharyya A, Alberta JA, Giannobile WV, Cheon K, Stiles CD, et al.: Activation of ErbB2 during Wallerian Degeneration of Sciatic Nerve. J Neurosci 1997, 17:8293-8299.
• [26]Zanazzi G, Einheber S, Westreich R, Hannocks MJ, Bedell-Hogan D, Marchionni MA, et al.: Glial Growth Factor/Neuregulin Inhibits Schwann Cell Myelination and Induces Demyelination. J Cell Biol 2001, 152:1289-1300.
• [27]Huijbregts RPH, Roth KA, Schmidt RE, Carroll SL: Hypertrophic Neuropathies and Malignant Peripheral Nerve Sheath Tumors in Transgenic Mice Overexpressing Glial Growth Factor β3 in Myelinating Schwann Cells. The Journal of Neuroscience 2003, 23:7269-7280.
• [28]Garratt AN, Voiculescu O, Topilko P, Charnay P, Birchmeier C: A Dual Role of erbB2 in Myelination and in Expansion of the Schwann Cell Precursor Pool. J Cell Biol 2000, 148:1035-1046.
• [29]Chen S, Velardez MO, Warot X, Yu ZX, Miller SJ, Cros D, et al.: Neuregulin 1-erbB Signaling Is Necessary for Normal Myelination and Sensory Function. J Neurosci 2006, 26:3079-3086.
• [30]Quintes S, Goebbels S, Saher G, Schwab MH, Nave KA: Neuron-glia signaling and the protection of axon function by Schwann cells. J Peripher Nerv Syst 2010, 15:10-16.
• [31]Jessen KR, Mirsky R: Negative regulation of myelination: relevance for development, injury, and demyelinating disease. Glia 2008, 56:1552-1565.
• [32]Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, et al.: Control of Peripheral Nerve Myelination by the β-Secretase BACE1. Science 2006, 314:664-666.
• [33]Hu X, He W, Diaconu C, Tang X, Kidd GJ, Macklin WB, et al.: Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. The FASEB Journal 2008, 22:2970-2980.
• [34]Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, et al.: Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 2006, 9:1520-1525.
• [35]Farah MH, Pan BH, Hoffman PN, Ferraris D, Tsukamoto T, Nguyen T, et al.: Reduced BACE1 activity enhances clearance of myelin debris and regeneration of axons in the injured peripheral nervous system. J Neurosci 2011, 31:5744-5754.
• [36]McKerracher L, David S, Jackson DL, Kottis V, Dunn RJ, Braun PE: Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron 1994, 13:805-811.
• [37]Mukhopadhyay G, Doherty P, Walsh FS, Crocker PR, Filbin MT: A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron 1994, 13:757-767.
• [38]Bahr M, Przyrembel C: Myelin from Peripheral and Central Nervous System Is a Nonpermissive Substrate for Retinal Ganglion Cell Axons. Experimental Neurology 1995, 134:87-93.
• [39]Shen YJ, DeBellard ME, Salzer JL, Roder J, Filbin MT: Myelin-associated glycoprotein in myelin and expressed by Schwann cells inhibits axonal regeneration and branching. Mol Cell Neurosci 1998, 12:79-91.
• [40]Schafer M, Fruttiger M, Montag D, Schachner M, Martini R: Disruption of the gene for the myelin-associated glycoprotein improves axonal regrowth along myelin in C57BL/Wlds mice. Neuron 1996, 16:1107-1113.
• [41]Bisby MA, Chen S: Delayed wallerian degeneration in sciatic nerves of C57BL/Ola mice is associated with impaired regeneration of sensory axons. Brain Res 1990, 530:117-120.
• [42]Brown MC, Perry VH, Lunn ER, Gordon S, Heumann R: Macrophage dependence of peripheral sensory nerve regeneration: possible involvement of nerve growth factor. Neuron 1991, 6:359-370.
• [43]Brown MC, Perry VH, Hunt SP, Lapper SR: Further studies on motor and sensory nerve regeneration in mice with delayed Wallerian degeneration. Eur J Neurosci 1994, 6:420-428.
• [44]Caroni P, Schwab ME: Two membrane protein fractions from rat central myelin with inhibitory properties for neurite growth and fibroblast spreading. J Cell Biol 1988, 106:1281-1288.
• [45]Cafferty WBJ, Duffy P, Huebner E, Strittmatter SM: MAG and OMgp Synergize with Nogo-A to Restrict Axonal Growth and Neurological Recovery after Spinal Cord Trauma. J Neurosci 2010, 30:6825-6837.
• [46]Lee JK, Geoffroy CG, Chan AF, Tolentino KE, Crawford MJ, Leal MA, et al.: Assessing spinal axon regeneration and sprouting in Nogo-, MAG-, and OMgp-deficient mice. Neuron 2010, 66:663-670.
• [47]David S, Aguayo AJ: Axonal elongation into peripheral nervous system "bridges" after central nervous system injury in adult rats. Science 1981, 214:931-933.
• [48]David S, Aguayo AJ: Axonal regeneration after crush injury of rat central nervous system fibres innervating peripheral nerve grafts. J Neurocytol 1985, 14:1-12.
• [49]Yiu G, He Z: Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 2006, 7:617-627.
• [50]Cao Z, Gao Y, Deng K, Williams G, Doherty P, Walsh FS: Receptors for myelin inhibitors: Structures and therapeutic opportunities. Mol Cell Neurosci 2010, 43:1-14.
• [51]Giger RJ, Hollis ER, Tuszynski MH: Guidance molecules in axon regeneration. Cold Spring Harb Perspect Biol 2010, 2:a001867.
• [52]Ramaglia V, King RHM, Nourallah M, Wolterman R, de Jonge R, Ramkema M, et al.: The Membrane Attack Complex of the Complement System Is Essential for Rapid Wallerian Degeneration. J Neurosci 2007, 27:7663-7672.
• [53]Bruck W, Bruck Y, Diederich U, Piddlesden SJ: The membrane attack complex of complement mediates peripheral nervous system demyelination in vitro. Acta Neuropathol (Berl) 1995, 90:601-607.
• [54]Mead RJ, Singhrao SK, Neal JW, Lassmann H, Morgan BP: The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol 2002, 168:458-465.
• [55]Stoll G, Griffin JW, Li CY, Trapp BD: Wallerian degeneration in the peripheral nervous system: participation of both Schwann cells and macrophages in myelin degradation. J Neurocytol 1989, 18:671-683.
• [56]George R, Griffin JW: Delayed Macrophage Responses and Myelin Clearance during Wallerian Degeneration in the Central Nervous System: The Dorsal Radiculotomy Model. Experimental Neurology 1994, 129:225-236.
• [57]Perry VH, Tsao JW, Fearn S, Brown MC: Radiation-induced reductions in macrophage recruitment have only slight effects on myelin degeneration in sectioned peripheral nerves of mice. Eur J Neurosci 1995, 7:271-280.
• [58]Fernandez-Valle C, Bunge RP, Bunge MB: Schwann cells degrade myelin and proliferate in the absence of macrophages: evidence fromin vitro studies of Wallerian degeneration. Journal of Neurocytology 1995, 24:667-679.
• [59]Rotshenker S: Microglia and Macrophage Activation and the Regulation of Complement-Receptor-3 (CR3/MAC-1)-Mediated Myelin Phagocytosis in Injury and Disease. J Mol Neurosci 2003, 21:65-72.
• [60]Be'eri H, Reichert F, Saada A, Rotshenker S: The cytokine network of wallerian degeneration: IL-10 and GM-CSF. Eur J Neurosci 1998, 10:2707-2713.
• [61]Carroll SL, Frohnert PW: Expression of JE (monocyte chemoattractant protein-1) is induced by sciatic axotomy in wild type rodents but not in C57BL/Wld(s) mice. J Neuropathol Exp Neurol 1998, 57:915-930.
• [62]Subang MC, Richardson PM: Influence of injury and cytokines on synthesis of monocyte chemoattractant protein-1 mRNA in peripheral nervous tissue. Eur J Neurosci 2001, 13:521-528.
• [63]Shamash S, Reichert F, Rotshenker S: The Cytokine Network of Wallerian Degeneration: Tumor Necrosis Factor- α, Interleukin-1α, and Interleukin-1β. J Neurosci 2002, 22:3052-3060.
• [64]Perry VH, Brown MC, Gordon S: The macrophage response to central and peripheral nerve injury. A possible role for macrophages in regeneration. J Exp Med 1987, 165:1218-1223.
• [65]Bendszus M, Stoll G: Caught in the act: in vivo mapping of macrophage infiltration in nerve injury by magnetic resonance imaging. J Neurosci 2003, 23:10892-10896.
• [66]Ransohoff RM: Chemokines in neurological disease models: correlation between chemokine expression patterns and inflammatory pathology. J Leukoc Biol 1997, 62:645-652.
• [67]Siebert H, Sachse A, Kuziel WA, Maeda N, Bruck W: The chemokine receptor CCR2 is involved in macrophage recruitment to the injured peripheral nervous system. Journal of Neuroimmunology 2000, 110:177-185.
• [68]Perrin FE, Lacroix S, Aviles-Trigueros M, David S: Involvement of monocyte chemoattractant protein-1, macrophage inflammatory protein-1α and interleukin-1β in Wallerian degeneration. Brain 2005, 128:854-866.
• [69]Siebert H, Dippel N, Mäder M, Weber F, Bruck W: Matrix metalloproteinase expression and inhibition after sciatic nerve axotomy. Journal of Neuropathology and Experimental Neurology 2001, 60:85-93.
• [70]Shubayev VI, Angert M, Dolkas J, Campana WM, Palenscar K, Myers RR: TNFα-induced MMP-9 promotes macrophage recruitment into injured peripheral nerve. Molecular and Cellular Neuroscience 2006, 31:407-415.
• [71]Chattopadhyay S, Myers RR, Janes J, Shubayev V: Cytokine regulation of MMP-9 in peripheral glia: Implications for pathological processes and pain in injured nerve. Brain, Behavior, and Immunity 2007, 21:561-568.
• [72]Fleur ML, Underwood JL, Rappolee DA, Werb Z: Basement Membrane and Repair of Injury to Peripheral Nerve: Defining a Potential Role for Macrophages, Matrix Metalloproteinases, and Tissue Inhibitor of Metalloproteinases-1. The Journal of Experimental Medicine 1996, 184:2311-2326.
• [73]Bruck W, Friede RL: The role of complement in myelin phagocytosis during PNS wallerian degeneration. Journal of the Neurological Sciences 1991, 103:182-187.
• [74]Dailey AT, Avellino AM, Benthem L, Silver J, Kliot M: Complement Depletion Reduces Macrophage Infiltration and Activation during Wallerian Degeneration and Axonal Regeneration. J Neurosci 1998, 18:6713-6722.
• [75]Liu L, Lioudyno M, Tao R, Eriksson P, Svensson M, Aldskogius H: Hereditary absence of complement C5 in adult mice influences wallerian degeneration, but not retrograde responses, following injury to peripheral nerve. Journal of the Peripheral Nervous System 1999, 4:123-133.
• [76]van der Laan LJ, Ruuls SR, Weber KS, Lodder IJ, Dopp EA, Dijkstra CD: Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-α and nitric oxide. J Neuroimmunol 1996, 70:145-152.
• [77]da Costa CC, van der Laan LJ, Dijkstra CD, Bruck W: The role of the mouse macrophage scavenger receptor in myelin phagocytosis. Eur J Neurosci 1997, 9:2650-2657.
• [78]Reichert F, Slobodov U, Makranz C, Rotshenker S: Modulation (inhibition and augmentation) of complement receptor-3- mediated myelin phagocytosis. Neurobiol Dis 2001, 8:504-512.
• [79]Reichert F, Rotshenker S: Complement-receptor-3 and scavenger-receptor-AI/II mediated myelin phagocytosis in microglia and macrophages. Neurobiol Dis 2003, 12:65-72.
• [80]Smith ME: Phagocytic properties of microglia in vitro: implications for a role in multiple sclerosis and EAE. Microsc Res Tech 2001, 54:81-94.
• [81]Vargas ME, Watanabe J, Singh SJ, Robinson WH, Barres BA: Endogenous antibodies promote rapid myelin clearance and effective axon regeneration after nerve injury. Proc Natl Acad Sci USA 2010, 107:11993-11998.
• [82]Saada A, Reichert F, Rotshenker S: Granulocyte macrophage colony stimulating factor produced in lesioned peripheral nerves induces the up-regulation of cell surface expression of MAC-2 by macrophages and Schwann cells. J Cell Biol 1996, 133:159-167.
• [83]Reichert F, Rotshenker S: Deficient activation of microglia during optic nerve degeneration. J Neuroimmunol 1996, 70:153-161.
• [84]Reichert F, Rotshenker S: Galectin-3/MAC-2 in experimental allergic encephalomyelitis. Exp Neurol 1999, 160:508-514.
• [85]Gitik M, Liraz ZS, Oldenborg PA, Reichert F, Rotshenker S: Myelin down-regulates myelin phagocytosis by microglia and macrophages through interactions between CD47 on myelin and SIRPα (signal regulatory protein-α) on phagocytes. J Neuroinflammation 2011, 8:24. BioMed Central Full Text
• [86]Reichert F, Levitzky R, Rotshenker S: Interleukin 6 in intact and injured mouse peripheral nerves. Eur J Neurosci 1996, 8:530-535.
• [87]Rotshenker S, Aamar S, Barak V: Interleukin-1 activity in lesioned peripheral nerve. J Neuroimmunol 1992, 39:75-80.
• [88]Mirski R, Reichert F, Klar A, Rotshenker S: Granulocyte macrophage colony stimulating factor (GM-CSF) activity is regulated by a GM-CSF binding molecule in Wallerian degeneration following injury to peripheral nerve axons. Journal of Neuroimmunology 2003, 140:88-96.
• [89]Baitsch D, Bock HH, Engel T, Telgmann R, Muller-Tidow C, Varga G, et al.: Apolipoprotein E Induces Antiinflammatory Phenotype in Macrophages. Arterioscler Thromb Vasc Biol 2011.
• [90]Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M, et al.: Macrophage plasticity in experimental atherosclerosis. PLoS One 2010, 5:e8852.
• [91]MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, et al.: Regulation of Alternative Macrophage Activation by Galectin-3. J Immunol 2008, 180:2650-2658.
• [92]Aamar S, Saada A, Rotshenker S: Lesion-induced changes in the production of newly synthesized and secreted apo-E and other molecules are independent of the concomitant recruitment of blood-borne macrophages into injured peripheral nerves. J Neurochem 1992, 59:1287-1292.
• [93]Saada A, Dunaevsky-Hutt A, Aamar A, Reichert F, Rotshenker S: Fibroblasts that reside in mouse and frog injured peripheral nerves produce apolipoproteins. J Neurochem 1995, 64:1996-2003.
• [94]Boivin A, Pineau I, Barrette B, Filali M, Vallieres N, ivest S, et al.: Toll-Like Receptor Signaling Is Critical for Wallerian Degeneration and Functional Recovery after Peripheral Nerve Injury. The Journal of Neuroscience 2007, 27:12565-12576.
• [95]Tieu BC, Lee C, Sun H, Lejeune W, Recinos A, Ju X, et al.: An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. J Clin Invest 2009, 119:3637-3651.
• [96]Chui R, Dorovini-Zis K: Regulation of CCL2 and CCL3 expression in human brain endothelial cells by cytokines and lipopolysaccharide. J Neuroinflammation 2010, 7:1. BioMed Central Full Text
• [97]Mori K, Chano T, Yamamoto K, Matsusue Y, Okabe H: Expression of macrophage inflammatory protein-1α in Schwann cell tumors. Neuropathology 2004, 24:131-135.
• [98]Maurer M, von Stebut E: Macrophage inflammatory protein-1. The International Journal of Biochemistry & Cell Biology 2004, 36:1882-1886.
• [99]Isenberg JS, Roberts DD, Frazier WA: CD47: a new target in cardiovascular therapy. Arterioscler Thromb Vasc Biol 2008, 28:615-621.
• [100]Sarfati M, Fortin G, Raymond M, Susin S: CD47 in the immune response: role of thrombospondin and SIRP-α reverse signaling. Curr Drug Targets 2008, 9:842-850.
• [101]Matozaki T, Murata Y, Okazawa H, Ohnishi H: Functions and molecular mechanisms of the CD47-SIRPα signalling pathway. Trends Cell Biol 2009, 19:72-80.
• [102]Barclay AN: Signal regulatory protein alpha (SIRPα)/CD47 interaction and function. Curr Opin Immunol 2009, 21:47-52.
• [103]Levi-Montalcini R, Angeletti PU: Nerve growth factor. Physiological Reviews 1968, 48:534-569.
• [104]Silver JS, Hunter CA: gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol 2010, 88:1145-1156.
• [105]Zweifel LS, Kuruvilla R, Ginty DD: Functions and mechanisms of retrograde neurotrophin signalling. Nat Rev Neurosci 2005, 6:615-625.
• [106]Huang EJ, Reichardt LF: NEUROTROPHINS: Roles in Neuronal Development and Function1. Annu Rev Neurosci 2001, 24:677-736.
• [107]Mok SA, Lund K, Campenot RB: A retrograde apoptotic signal originating in NGF-deprived distal axons of rat sympathetic neurons in compartmented cultures. Cell Res 2009, 19:546-560.
• [108]Heumann R, Korsching S, Bandtlow C, Thoenen H: Changes of nerve growth factor synthesis in nonneuronal cells in response to sciatic nerve transection. J Cell Biol 1987, 104:1623-1631.
• [109]Lindholm D, Heumann R, Meyer M, Thoenen H: Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve. Nature 1987, 330:658-659.
• [110]Heumann R, Lindholm D, Bandtlow C, Meyer M, Radeke MJ, Misko TP, et al.: Differential regulation of mRNA encoding nerve growth factor and its receptor in rat sciatic nerve during development, degeneration, and regeneration: role of macrophages. Proc Natl Acad Sci USA 1987, 84:8735-8739.
• [111]Matsuoka I, Meyer M, Thoenen H: Cell-type-specific regulation of nerve growth factor (NGF) synthesis in non-neuronal cells: comparison of Schwann cells with other cell types. The Journal of Neuroscience 1991, 11:3165-3177.
• [112]DiStefano PS, Curtis R: Chapter 4 Receptor mediated retrograde axonal transport of neurotrophic factors is increased after peripheral nerve injury. In Progress in Brain Research Neural Regeneration. Edited by Fredrick JS. Elsevier; 1994:35-42. Volume 103 edition
• [113]Hattori A, Iwasaki S, Murase K, Tsujimoto M, Sato M, Hayashi K, et al.: Tumor necrosis factor is markedly synergistic with interleukin 1 and interferon-γ in stimulating the production of nerve growth factor in fibroblasts. FEBS Lett 1994, 340:177-180.
• [114]Bauer S, Kerr BJ, Patterson PH: The neuropoietic cytokine family in development, plasticity, disease and injury. Nat Rev Neurosci 2007, 8:221-232.
• [115]Murphy M, Dutton R, Koblar S, Cheema S, Bartlett P: Cytokines which signal through the LIF receptor and their actions in the nervous system. Progress in Neurobiology 1997, 52:355-378.
• [116]Banner LR, Patterson PH: Major changes in the expression of the mRNAs for cholinergic differentiation factor/leukemia inhibitory factor and its receptor after injury to adult peripheral nerves and ganglia. Proc Natl Acad Sci USA 1994, 91:7109-7113.
• [117]Curtis R, Scherer SS, Somogyi R, Adryan KM, Ip NY, Zhu Y, et al.: Retrograde axonal transport of LIF is increased by peripheral nerve injury: correlation with increased LIF expression in distal nerve. Neuron 1994, 12:191-204.
• [118]Hirota H, Kiyama H, Kishimoto T, Taga T: Accelerated Nerve Regeneration in Mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma. The Journal of Experimental Medicine 1996, 183:2627-2634.
• [119]Zhong J, Dietzel ID, Wahle P, Kopf M, Heumann R: Sensory Impairments and Delayed Regeneration of Sensory Axons in Interleukin-6-Deficient Mice. The Journal of Neuroscience 1999, 19:4305-4313.
• [120]Murphy PG, Borthwick LA, Altares M, Gauldie J, Kaplan D, Richardson PM: Reciprocal actions of interleukin-6 and brain-derived neurotrophic factor on rat and mouse primary sensory neurons. European Journal of Neuroscience 2000, 12:1891-1899.
• [121]Cheema SS, Richards L, Murphy M, Bartlett PF: Leukemia inhibitory factor prevents the death of axotomised sensory neurons in the dorsal root ganglia of the neonatal rat. J Neurosci Res 1994, 37:213-218.
• [122]Cafferty WBJ, Gardiner NJ, Gavazzi I, Powell J, McMahon SB, Heath JK, et al.: Leukemia Inhibitory Factor Determines the Growth Status of Injured Adult Sensory Neurons. The Journal of Neuroscience 2001, 21:7161-7170.
• [123]Dowsing BJ, Morrison WA, Nicola NA, Starkey GP, Bucci T, Kilpatrick TJ: Leukemia inhibitory factor is an autocrine survival factor for Schwann cells. J Neurochem 1999, 73:96-104.
• [124]Costigan M, Scholz J, Woolf CJ: Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci 2009, 32:1-32.
• [125]Woolf CJ: What is this thing called pain? J Clin Invest 2010, 120:3742-3744.
• [126]Zimmermann M: Pathobiology of neuropathic pain. Eur J Pharmacol 2001, 429:23-37.
• [127]Myers RR, Heckman HM, Rodriguez M: Reduced hyperalgesia in nerve-injured WLD mice: relationship to nerve fiber phagocytosis, axonal degeneration, and regeneration in normal mice. Exp Neurol 1996, 141:94-101.
• [128]Murphy PG, Ramer MS, Borthwick L, Gauldie J, Richardson PM, Bisby MA: Endogenous interleukin-6 contributes to hypersensitivity to cutaneous stimuli and changes in neuropeptides associated with chronic nerve constriction in mice. Eur J Neurosci 1999, 11:2243-2253.
• [129]Wu G, Ringkamp M, Murinson BB, Pogatzki EM, Hartke TV, Weerahandi HM, et al.: Degeneration of myelinated efferent fibers induces spontaneous activity in uninjured C-fiber afferents. J Neurosci 2002, 22:7746-7753.
• [130]Safieh-Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ: Contribution of interleukin-1β to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br J Pharmacol 1995, 115:1265-1275.
• [131]Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S: Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol 1997, 121:417-424.
• [132]Wagner R, Myers RR: Endoneurial injection of TNF-α produces neuropathic pain behaviors. Neuroreport 1996, 7:2897-2901.
• [133]Sorkin LS, Doom CM: Epineurial application of TNF elicits an acute mechanical hyperalgesia in the awake rat. Journal of the Peripheral Nervous System 2000, 5:96-100.
• [134]Zelenka M, Schafers M, Sommer C: Intraneural injection of interleukin-1β and tumor necrosis factor-α into rat sciatic nerve at physiological doses induces signs of neuropathic pain. Pain 2005, 116:257-263.
• [135]Leung L, Cahill C: TNF-α and neuropathic pain - a review. Journal of Neuroinflammation 2010, 7:27. BioMed Central Full Text
• [136]Ho MK, Springer TA: Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies. J Immunol 1982, 128:1221-1228.
• [137]Ashery U, Yizhar O, Rotblat B, Elad-Sfadia G, Barkan B, Haklai R, et al.: Spatiotemporal Organization of Ras Signaling: Rasosomes and the Galectin Switch. Cell Mol Neurobiol 2006, 26:471-495.
• [138]Yang RY, Rabinovich GA, Liu FT: Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 2008, 10:e17.
• [139]Sato S, St-Pierre C, Bhaumik P, Nieminen J: Galectins in innate immunity: dual functions of host soluble β-galactoside-binding lectins as damage-associated molecular patterns (DAMPs) and as receptors for pathogen-associated molecular patterns (PAMPs). Immunological Reviews 2009, 230:172-187.
• [140]Makranz C, Cohen G, Baron A, Levidor L, Kodama T, Reichert F, Rotshenker S: Phosphatidylinositol 3-kinase, phosphoinositide-specific phospholipase-Cγ and protein kinase-C signal myelin phagocytosis mediated by complement receptor-3 alone and combined with scavenger receptor-AI/II in macrophages. Neurobiol Dis 2004, 15:279-286.
• [141]Cohen G, Makranz C, Spira M, Kodama T, Reichert F, Rotshenker S: Non-PKC DAG/Phorbol-Ester receptor(s) inhibit complement receptor-3 and nPKC inhibit scavenger receptor-AI/II-mediated myelin phagocytosis but cPKC, PI3K, and PLCγ activate myelin phagocytosis by both. Glia 2006, 53:538-550.
• [142]Shalom-Feuerstein R, Plowman SJ, Rotblat B, Ariotti N, Tian T, Hancock JF, et al.: K-Ras Nanoclustering Is Subverted by Overexpression of the Scaffold Protein Galectin-3. Cancer Res 2008, 68:6608-6616.
• [143]Rotshenker S, Reichert F, Gitik M, Haklai R, Elad-Sfadia G, Kloog Y: Galectin-3/MAC-2, Ras and PI3K activate complement receptor-3 and scavenger receptor-AI/II mediated myelin phagocytosis in microglia. Glia 2008, 56:1607-1613.
• [144]Rotshenker S: The Role of Galectin-3/MAC-2 in the Activation of the Innate-Immune Function of Phagocytosis in Microglia in Injury and Disease. J Mol Neurosci 2009, 39:99-103.
• [145]Aderka D, Le JM, Vilcek J: IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989, 143:3517-3523.
• [146]Dinarello CA: Historical insights into cytokines. Eur J Immunol 2007, 37(Suppl 1):S34-S45.
• [147]Gordon S: Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
• [148]Mosser DM: The many faces of macrophage activation. J Leukoc Biol 2003, 73:209-212.
• [149]Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686.
• [150]Auffray C, Sieweke MH, Geissmann F: Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009, 27:669-692.
• [151]Benoit M, Desnues B, Mege JL: Macrophage Polarization in Bacterial Infections. J Immunol 2008, 181:3733-3739.
• [152]Geissmann F, Gordon S, Hume DA, Mowat AM, Randolph GJ: Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol 2010, 10:453-460.